Trevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The ...
I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called ...
Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments. The biopharmaceutical company posted a loss of $11.4 million, or 11 cents ...
Trevi had three positive and meaningful clinical data read-outs over the past few months validating the strategy of developing Haduvio as a ...
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) had its price target cut by stock analysts at Needham & Company LLC from ...
In a recent, cross-institutional study, researchers report that healthy human airways are at higher risk for dehydration and ...
In a recent, cross-institutional study partially funded by the National Institutes of Health, researchers report that healthy human airways are at higher risk for dehydration and inflammation when ...
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has been assigned an average recommendation of “Buy” from the ten ...
4d
News-Medical.Net on MSNDry air exposure linked to dehydration and inflammation in human airwaysIn a recent, cross-institutional study partially funded by the National Institutes of Health, researchers report that healthy ...
I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called mycobacterium avium complex. Would you kindly consider discussing this?
Kyorin Pharma has signed a deal with digital health firm Hyfe to develop a digital therapeutic (DTx) for people with chronic cough and launch it in Japan. Hyfe's platform uses artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results